210 related articles for article (PubMed ID: 32790610)
1. Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
Gupta MA; Vujcic B; Gupta AK
Skinmed; 2020; 18(3):146-150. PubMed ID: 32790610
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
3. Assessing finasteride-associated sexual dysfunction using the FAERS database.
Gupta AK; Carviel J; MacLeod MA; Shear N
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1069-1075. PubMed ID: 28300347
[TBL] [Abstract][Full Text] [Related]
4. Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study.
Ali AK; Heran BS; Etminan M
Pharmacotherapy; 2015 Jul; 35(7):687-95. PubMed ID: 26133534
[TBL] [Abstract][Full Text] [Related]
5. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
[TBL] [Abstract][Full Text] [Related]
6. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System.
Gupta AK; Carviel J; Gupta MA; Shear NH
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1373-1376. PubMed ID: 29194783
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.
Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B
World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745
[TBL] [Abstract][Full Text] [Related]
8. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
[TBL] [Abstract][Full Text] [Related]
9. Post-finasteride syndrome: a surmountable challenge for clinicians.
Traish AM
Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
[TBL] [Abstract][Full Text] [Related]
10. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
Wu M; Yu Q; Li Q
Oncotarget; 2016 Dec; 7(50):82074-82084. PubMed ID: 27738338
[TBL] [Abstract][Full Text] [Related]
11. Risk of Depression Associated With Finasteride Treatment.
Pompili M; Magistri C; Maddalena S; Mellini C; Persechino S; Baldessarini RJ
J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):304-309. PubMed ID: 33814544
[TBL] [Abstract][Full Text] [Related]
12. Finasteride and Suicide: A Postmarketing Case Series.
Irwig MS
Dermatology; 2020; 236(6):540-545. PubMed ID: 31935720
[TBL] [Abstract][Full Text] [Related]
13. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
14. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B
Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001
[TBL] [Abstract][Full Text] [Related]
15. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
Chiriacò G; Cauci S; Mazzon G; Trombetta C
Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
[TBL] [Abstract][Full Text] [Related]
16. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men.
Walf AA; Kaurejo S; Frye CA
Am J Mens Health; 2018 Jul; 12(4):900-906. PubMed ID: 29318957
[TBL] [Abstract][Full Text] [Related]
17. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
[TBL] [Abstract][Full Text] [Related]
18. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
Iamsumang W; Leerunyakul K; Suchonwanit P
Drug Des Devel Ther; 2020; 14():951-959. PubMed ID: 32184564
[TBL] [Abstract][Full Text] [Related]
19. [Finasteride adverse effects: An update].
Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
[TBL] [Abstract][Full Text] [Related]
20. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
